936243-40-2

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridin-3-aMine, 5-chloro-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridin-3-aMine, 5-chloro-;5-chloro-1H-pyrrolo[2,3-b]pyridin-3-amine;5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylamine
• CAS NO: 936243-40-2
• Molecular Formula: C7H6ClN3
• Molecular Weight: 167.59564
• Mol File: 936243-40-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridin-3-aMine, 5-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridin-3-aMine, 5-chloro-(936243-40-2)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridin-3-aMine, 5-chloro-(936243-40-2)

Safety Data

• Hazardous Substances Data: 936243-40-2(Hazardous Substances Data)

Usage

Derivative of pyrrolopyridine

The compound is derived from pyrrolopyridine, which is a heterocyclic compound consisting of a pyrrole ring fused to a pyridine ring.

Chlorine atom attached to the fifth carbon

The compound has a chlorine atom attached to the fifth carbon of the pyrrolopyridine ring, which can affect its chemical properties and reactivity.

Potential applications in pharmaceutical research and drug development

The compound can act as a building block for the synthesis of various biologically active molecules, making it potentially useful in the development of new drugs and therapies.

Safety protocols

It is important to handle this chemical with care and follow proper safety protocols when working with it in a laboratory setting to avoid exposure and potential health risks.

Upstream product

• 1033463-33-0 5-chloro-3-nitro-1H-pyrrolo[2,3-b]pyridine 
• 936243-18-4 5-chloro-3-nitroso-1H-pyrrolo[2,3-b]pyridine 
• 866546-07-8 5-chloro-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1449321-07-6 1-benzyl-1H-pyrazol-4-carboxylic acid (5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)amide 
• 1449321-10-1 1-(4-fluorobenzyl)-1H-pyrazol-4-carboxylic acid (5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)amide 

Relevant articles and documents

1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS

The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.

Design, synthesis, and biological evaluation of substituted-N-(thieno[2,3-b]pyridin-3-yl)-guanidines, N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidines, and N-(1H-indol-3-yl)-guanidines

Sulfonylureas stimulate insulin secretion independent of the blood glucose concentration and therefore cause hypoglycemia in type 2 diabetic patients. Over the last years, a number of aryl-imidazoline derivatives have been identified that stimulate insulin secretion in a glucose-dependent manner. In the present study, we have developed three series of substituted N-(thieno[2,3-b]pyridin-3-yl)-guanidine (2a-l), N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3a-l), and N-(1H-indol-3-yl)-guanidine (4a-l) as new class of antidiabetic agents. In vitro glucose-dependent insulinotropic activity of test compounds 2a-l, 3a-l, and 4a-l was evaluated using RIN5F (Rat Insulinoma cell) based assay. All the test compounds showed concentration-dependent insulin secretion, only in presence of glucose load (16.7 mmol). Some of the test compounds (2c, 3c, and 4c) from each series were found to be equipotent to BL 11282 (standard aryl-imidazoline), which indicated that the guanidine group acts as a bioisostere of imidazoline ring system.